HDL and cancer - causality still needs to be confirmed? Update 2020.

Ganjali, Shiva; Banach, Maciej; Pirro, Matteo; Fras, Zlatko; Sahebkar, Amirhossein

Ganjali, Shiva; Banach, Maciej; Pirro, Matteo; Fras, Zlatko; Sahebkar, Amirhossein.

Affiliation

Ganjali S; Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Banach M; Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. Electronic address: maciejbanach77@gmail.com.
Pirro M; Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy.
Fras Z; Division of Medicine, Department of Vascular Medicine, Centre for Preventive Cardiology, University Medical Centre Ljubljana, Zaloska 7, 1525, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Sahebkar A; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Halal Research Center of IRI, FDA, Tehran, Iran. Electronic address: sahebkara@mu

Semin Cancer Biol ; 73: 169-177, 2021 08.

Article in En | MEDLINE | ID: mdl-33130036

Subject(s)

Cholesterol, HDL; Neoplasms; Animals; Humans; Risk Factors

Key words

Apolipoproteina; Cancer; High-density lipoprotein (HDL)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Cholesterol, HDL / Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Semin Cancer Biol Journal subject: NEOPLASIAS Year: 2021 Type: Article Affiliation country: Iran

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google